|
Gene: NABP1 |
Gene summary for NABP1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | NABP1 | Gene ID | 64859 |
Gene name | nucleic acid binding protein 1 | |
Gene Alias | OBFC2A | |
Cytomap | 2q32.3 | |
Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | Q96AH0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64859 | NABP1 | LZE4T | Human | Esophagus | ESCC | 5.64e-15 | 6.53e-01 | 0.0811 |
64859 | NABP1 | LZE7T | Human | Esophagus | ESCC | 7.34e-09 | 4.09e-01 | 0.0667 |
64859 | NABP1 | LZE8T | Human | Esophagus | ESCC | 3.02e-07 | 4.10e-01 | 0.067 |
64859 | NABP1 | LZE20T | Human | Esophagus | ESCC | 9.97e-04 | 2.54e-01 | 0.0662 |
64859 | NABP1 | LZE24T | Human | Esophagus | ESCC | 3.99e-20 | 9.53e-01 | 0.0596 |
64859 | NABP1 | LZE21T | Human | Esophagus | ESCC | 5.44e-05 | 5.42e-01 | 0.0655 |
64859 | NABP1 | LZE6T | Human | Esophagus | ESCC | 2.44e-16 | 4.81e-01 | 0.0845 |
64859 | NABP1 | P1T-E | Human | Esophagus | ESCC | 2.24e-09 | 4.88e-01 | 0.0875 |
64859 | NABP1 | P2T-E | Human | Esophagus | ESCC | 1.94e-11 | 1.43e-01 | 0.1177 |
64859 | NABP1 | P4T-E | Human | Esophagus | ESCC | 1.70e-11 | 3.12e-01 | 0.1323 |
64859 | NABP1 | P5T-E | Human | Esophagus | ESCC | 6.87e-20 | 5.47e-01 | 0.1327 |
64859 | NABP1 | P8T-E | Human | Esophagus | ESCC | 8.12e-10 | 2.68e-01 | 0.0889 |
64859 | NABP1 | P9T-E | Human | Esophagus | ESCC | 1.93e-18 | 4.19e-01 | 0.1131 |
64859 | NABP1 | P10T-E | Human | Esophagus | ESCC | 2.25e-14 | 2.49e-01 | 0.116 |
64859 | NABP1 | P11T-E | Human | Esophagus | ESCC | 6.17e-12 | 5.87e-01 | 0.1426 |
64859 | NABP1 | P12T-E | Human | Esophagus | ESCC | 5.15e-22 | 5.99e-01 | 0.1122 |
64859 | NABP1 | P15T-E | Human | Esophagus | ESCC | 2.83e-28 | 7.29e-01 | 0.1149 |
64859 | NABP1 | P16T-E | Human | Esophagus | ESCC | 6.96e-06 | 1.70e-02 | 0.1153 |
64859 | NABP1 | P20T-E | Human | Esophagus | ESCC | 2.43e-09 | 2.44e-01 | 0.1124 |
64859 | NABP1 | P21T-E | Human | Esophagus | ESCC | 4.86e-09 | 2.24e-01 | 0.1617 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
GO:001021217 | Esophagus | ESCC | response to ionizing radiation | 110/8552 | 148/18723 | 1.11e-12 | 4.78e-11 | 110 |
GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
GO:00000754 | Esophagus | ESCC | cell cycle checkpoint | 117/8552 | 169/18723 | 4.47e-10 | 1.17e-08 | 117 |
GO:00448394 | Esophagus | ESCC | cell cycle G2/M phase transition | 103/8552 | 148/18723 | 3.09e-09 | 6.67e-08 | 103 |
GO:00000864 | Esophagus | ESCC | G2/M transition of mitotic cell cycle | 96/8552 | 137/18723 | 6.00e-09 | 1.23e-07 | 96 |
GO:00070934 | Esophagus | ESCC | mitotic cell cycle checkpoint | 90/8552 | 129/18723 | 2.49e-08 | 4.69e-07 | 90 |
GO:00109484 | Esophagus | ESCC | negative regulation of cell cycle process | 177/8552 | 294/18723 | 3.26e-07 | 4.59e-06 | 177 |
GO:19019883 | Esophagus | ESCC | negative regulation of cell cycle phase transition | 151/8552 | 249/18723 | 1.28e-06 | 1.57e-05 | 151 |
GO:00063024 | Esophagus | ESCC | double-strand break repair | 152/8552 | 251/18723 | 1.33e-06 | 1.62e-05 | 152 |
GO:004593013 | Esophagus | ESCC | negative regulation of mitotic cell cycle | 143/8552 | 235/18723 | 1.84e-06 | 2.15e-05 | 143 |
GO:190199113 | Esophagus | ESCC | negative regulation of mitotic cell cycle phase transition | 112/8552 | 179/18723 | 3.69e-06 | 4.03e-05 | 112 |
GO:00103891 | Esophagus | ESCC | regulation of G2/M transition of mitotic cell cycle | 64/8552 | 94/18723 | 9.21e-06 | 8.82e-05 | 64 |
GO:19027491 | Esophagus | ESCC | regulation of cell cycle G2/M phase transition | 68/8552 | 102/18723 | 1.48e-05 | 1.33e-04 | 68 |
GO:00109721 | Esophagus | ESCC | negative regulation of G2/M transition of mitotic cell cycle | 41/8552 | 60/18723 | 3.25e-04 | 1.91e-03 | 41 |
GO:19027501 | Esophagus | ESCC | negative regulation of cell cycle G2/M phase transition | 42/8552 | 62/18723 | 3.69e-04 | 2.14e-03 | 42 |
Page: 1 2 3 4 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NABP1 | deletion | Frame_Shift_Del | novel | c.509delA | p.Asn170MetfsTer6 | p.N170Mfs*6 | Q96AH0 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
NABP1 | insertion | Frame_Shift_Ins | novel | c.375_376insG | p.Ala127GlyfsTer4 | p.A127Gfs*4 | Q96AH0 | protein_coding | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
NABP1 | SNV | Missense_Mutation | novel | c.469N>A | p.Glu157Lys | p.E157K | Q96AH0 | protein_coding | tolerated(0.39) | benign(0.053) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
NABP1 | SNV | Missense_Mutation | novel | c.37G>T | p.Asp13Tyr | p.D13Y | Q96AH0 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NABP1 | SNV | Missense_Mutation | novel | c.550N>G | p.Ser184Gly | p.S184G | Q96AH0 | protein_coding | tolerated(0.32) | benign(0) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NABP1 | SNV | Missense_Mutation | rs768187242 | c.514N>T | p.Arg172Trp | p.R172W | Q96AH0 | protein_coding | deleterious(0.02) | benign(0.007) | TCGA-AX-A2HG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NABP1 | SNV | Missense_Mutation | c.369N>T | p.Gln123His | p.Q123H | Q96AH0 | protein_coding | deleterious(0.03) | benign(0.443) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NABP1 | SNV | Missense_Mutation | novel | c.82C>A | p.Leu28Met | p.L28M | Q96AH0 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
NABP1 | SNV | Missense_Mutation | c.85N>A | p.Glu29Lys | p.E29K | Q96AH0 | protein_coding | deleterious(0) | benign(0.398) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
NABP1 | SNV | Missense_Mutation | c.57A>T | p.Lys19Asn | p.K19N | Q96AH0 | protein_coding | deleterious(0) | probably_damaging(0.934) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |